NCT01255709View on ClinicalTrials.gov

Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Asthma
Interventions
DRUG

Arm T1: Primatene Mist HFA

epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes

DRUG

Arm T2: Primatene Mist HFA

epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes

DRUG

Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)

epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes

Trial Locations (1)

90630

Amphastar Study Site 1, Cypress

Sponsors
All Listed Sponsors
lead

Amphastar Pharmaceuticals, Inc.

INDUSTRY